Clinical trials: Schizophrenia
Schizophrenia
Extension Study: Evaluating the Safety of Oral Ziprasidone in the Treatment of Subjects With Schizophrenia
To provide treatment to eligible subjects who have successfully completed one of the following phase III ziprasidone studies, A1281028, A1281044, A1281045 (NCT00136994) or A1281088 (NCT00143351).
- Trial name
- NCT00139737
- Testing
- Ziprasidone
- Where
- 87 sites in Italy
- Volunteers
- 344 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia
24-Week Open Label Extension to a Randomized, 6-Week Double Blind, Placebo Controlled Study, to Evaluate the Safety and Tolerability of Flexible Doses of Extended Release OROS® Paliperidone in the Treatment of Geriatric Subjects With Schizophrenia
The purpose of this open-label study was to evaluate the safety and tolerability of flexible doses of Extended Release OROS® Paliperidone in the treatment of geriatric subjects with schizophrenia after completion of the initial…
- Trial name
- NCT00752427
- Testing
- Paliperidone ER OROS®
- Volunteers
- 86 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Pediatric
Safety, Tolerability, and Pharmacokinetics of Lumateperone in Pediatric Patients With Schizophrenia or Schizoaffective Disorder
Study ITI-007-020 is a Phase 1b, multicenter, open-label study to evaluate the safety, tolerability, and PK of lumateperone as treatment for adolescent patients with schizophrenia or schizoaffective disorder.
- Trial name
- NCT04779177
- Testing
- Lumateperone 42 mg, Lumateperone 28 mg
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Schizophrenia, Bipolar Disorder
An Observational Study of Olanzapine Coated and Orodispersible Tablets Effectiveness in Schizophrenic and Bipolar Outpatients.
The primary objective of this study is to assess the proportion of schizophrenic patients and the proportion of bipolar patients who discontinue olanzapine within 12 months of treatment in outpatient, ambulatory or community…
- Trial name
- NCT00510211
- Testing
- olanzapine
- Where
- 3 sites in France, Germany and 1 more
- Volunteers
- 1,131 people
- Sponsor
- Eli Lilly and Company
Schizophrenia
Mozart Relapse Study
To assess the long-term efficacy of oral Ziprasidone in the maintenance treatment of resistant schizophrenic subjects who have benefited from participation in the phase III ziprasidone study A1281039 (MOZART study), to assess the…
- Trial name
- NCT00143351
- Testing
- Ziprasidone
- Where
- 16 sites in Italy
- Volunteers
- 75 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia
Investigate Risperidone for the Treatment of Schizophrenia in Adolescents
A clinical study to evaluate the efficacy, safety and tolerability of two dose ranges of risperidone (1 to 3 mg/day, and 4 to 6 mg/day) versus placebo (an inactive substance like a sugar pill) in adolescents (aged 13 to 17 years)…
- Trial name
- NCT00088075
- Testing
- Risperidone
- Volunteers
- 160 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Efficacy and Safety Study of Aripiprazole to Treat Schizophrenia
This study design is subject to relevant SFDA regulations about clinical trials. Patients will be screened for inclusion into the study at the initial visit(240 patients to be recruited) and then undergo a minimum of 3-7 day's…
- Trial name
- NCT00202007
- Testing
- Aripiprazole tablet, 5-30mg/day, oral, 6 weeks, Risperidone tablet, 1-6mg/day, oral, 6 weeks
- Where
- 6 sites in China
- Volunteers
- 240 people
- Sponsor
- Otsuka Beijing Research Institute
Schizophrenia
Paliperidone Extended Release in Schizophrenia Participants With Duration of Illness Less Than 10 Years
The purpose of this study is to evaluate the effectiveness and safety of paliperidone extended release (ER) in symptomatic participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment…
- Trial name
- NCT01362439
- Testing
- Paliperidone ER
- Volunteers
- 133 people
- Sponsor
- Janssen-Cilag S.p.A.
Schizophrenia
Real-World Impact of TV-44749 in Adults With Schizophrenia
The main purpose of this trial is to evaluate how TV-44749 (olanzapine long-acting injectable) works in routine clinical practice for adults with schizophrenia.
- Trial name
- RADIANCE (NCT07913100)
- Testing
- TV-44749
- Volunteers
- 1,085 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Schizophrenia
A Study Evaluating the of OPC-34712 in Subjects With Normal Hepatic Function and Hepatically Impaired Subjects
The purpose of this study is to evaluate how much of the investigational product gets into the blood stream and how long the body takes to get rid of it when given to subjects with a range of liver impairment compared to subjects…
- Trial name
- NCT01299454
- Testing
- OPC-34712
- Where
- 3 sites in United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A Healthy Volunteer Study to Assess the Relative Bioavailability of 2 Forms of SB773812 Tablets.
Study to compare PK of a new 120mg tablet with two 60mg tablets. This is required because we plan to have only single tablets administered in the later phase clinical trials but we have not had a 120mg strength before.
- Trial name
- NCT00500201
- Testing
- SB- 773812 60 mg, SB- 773812 120 mg
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Schizophrenia, Schizoaffective Disorder
Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia
The current study has been designed to address the significance of early onset of response prospectively in patients treated with an atypical antipsychotic.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00337662
- Testing
- olanzapine, risperidone
- Where
- 34 sites in United States, Argentina and 1 more
- Volunteers
- 628 people
- Sponsor
- Eli Lilly and Company
Schizophrenia
Safety, PK and PD Study in Healthy Male Japanese Subjects
Study assessing pharmacokinetics, pharmacodynamics, safety, and tolerability of oral doses of SCA-136 in healthy male Japanese subjects
- Trial name
- NCT00447941
- Testing
- SCA-136
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Schizophrenia
Efficacy and Safety of Armodafinil as Adjunctive Therapy in Schizophrenic Adults With Cognitive Deficits
The primary objective of this study is to evaluate if adjunctive armodafinil treatment can improve the cognitive deficits in patients with schizophrenia
- Trial name
- NCT00487942
- Testing
- armodafinil
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Cephalon
Schizophrenia
Study to Assess the Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of EVP-6308 and the Potential of EVP-6308 to Affect the PK Properties of the Antipsychotic Regimen in Subjects With Schizophrenia Currently Receiving Stable Treatment With up to 2 Atypical Antipsychotics
This is a randomized, double-blind, placebo-controlled, sequential cohort, ascending oral dose study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of EVP-6308 administered for 14 days in subjects with…
- Trial name
- NCT02037074
- Testing
- Drug: EVP-6308
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- FORUM Pharmaceuticals Inc
Bipolar 1 Disorder, Schizophrenia Disorder
An Expanded Access Program (EAP) for OLZ/SAM in Pediatric Participants With Schizophrenia or Bipolar I Disorder (ALKS 3831-315)
To provide continued access to OLZ/SAM for pediatric participants with schizophrenia or bipolar I disorder who have completed participation in the ALKS 3831-A313 long-term safety extension study.
- Trial name
- NCT07744113
- Testing
- OLZ/SAM
- Where
- United States
- Sponsor
- Alkermes, Inc.
Schizophrenia
Exploratory Study of a Digital Therapeutics in People With Schizophrenia
CT-155 is a novel prescription digital therapeutic (PDT) being developed by Click Therapeutics, Inc. (Click) and Boehringer Ingelheim (BI) using an interactive, software-based intervention to treat schizophrenia
- Trial name
- NCT05438160
- Testing
- Clinical Learning Study smartphone app (i.e., the study app)
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Click Therapeutics, Inc.
Schizophrenia, Psychotic Disorders
Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
The primary objective is to compare effectiveness of ziprasidone treatment to current treatments (haloperidol, olanzapine or risperidone) measured by change in Brief Psychiatric Rating Scale (BPRS) scores versus baseline
- Trial name
- NCT00137020
- Testing
- ziprasidone
- Where
- 27 sites in Egypt, Greece and 7 more
- Volunteers
- 294 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia, Bipolar Disorders
The Purpose of the Study is to Gain an In-depth Picture of the Patient Management and Prescription Behaviours
'Real life' retrospective patient cases (10) to provide an objective and robust analytical report of patient management and prescriptions behaviours for Schizophrenia, Bipolar disorders and Major depressive disorders.
- Conditions
- Schizophrenia, Bipolar Disorders, Major Depressive Disorders
- Trial name
- NCT01377896
- Volunteers
- 221 people
- Sponsor
- AstraZeneca
Agitation,Psychomotor, Bipolar I Disorder
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)
In this study, an investigational medication named BXCL501 is being tested for the treatment of episodes of agitation associated with bipolar I and bipolar II disorder, schizophrenia, schizoaffective and schizophreniform…
- Conditions
- Agitation,Psychomotor, Bipolar I Disorder, Bipolar II Disorder, Schizophrenia
- Trial name
- NCT05658510
- Testing
- BXCL501
- Where
- 24 sites in United States
- Volunteers
- 452 people
- Sponsor
- BioXcel Therapeutics Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.